This is because of the difficulty in algorithmically detecting single exon deletion and insertion/duplication events, and it is likely that this class of mutation is currently being under-reported by most NGS-based BRCA1/2 assays, in particular, tumor assays using clinical FFPE samples of low tumor cellularity. The gene discussed is BRCA1; the disease is neoplasm.